Inhaled pharmacokinetics

Ramsey JC, Andersen ME. 1984. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol Appl Pharmacol 73 159-175. [Pg.286]

Prah, J., Ashley, D., Blount, B., Case, M., Leavens, T., Pleil, J., and Cardinali, F., Dermal, oral, and inhalation pharmacokinetics of methyl tertiary butyl ether (MTBE) in human volunteers, Toxicological Sciences, 77, 195-205, 2004. [Pg.1050]

Auton TR, Woollen BH A physiologically based mathematical model for the human inhalation pharmacokinetics of 1,1,2-trichloro-l,2,2-trifluoroethane. Int Arch Occup Environ Health 63 133-138, 1991... [Pg.705]

Uemitsu N. 1986. Inhalation pharmacokinetics of carbon tetrachloride in rats based on arterial blood inhaled air concentration ratios. Toxicol AppI Pharmacol 83 20-29. [Pg.188]

Beliveau, M., Lipscomb, J., Tardif, R. and Krishnan, K. (2005) Quantitative structure-property relationships for inter species extrapolation of the inhalation pharmacokinetics of organic chemicals. Chem. Res. Toxicol.,... [Pg.41]

Filser, J.C. Bolt, H.M. (1984) Inhalation pharmacokinetics based on gas uptake studies VI. Comparative evaluation of ethylene oxide and butadiene monoxide as exhaled reactive metabolites of ethylene and 1,3-butadiene in rats. Arch. Toxicol., 55, 219-223... [Pg.208]

Kreiling, R., Laib. R.J., Filser, J.G Bolt, H.M. (1987) Inhalation pharmacokinetics of 1,2-epoxybutene-3 reveal species differences between rats and mice sensitive to butadiene-induced carcinogenesis. Arch. Toxicol., 61, 7-11... [Pg.212]

Ramsey, J.C. Andersen, M.E. (1984) A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol, appl. Pharmacol., T3, 159-175 Rappaport, S.M., Ting, D., Jin, Z., Yeowell-0 Connell, K., Waidyanatha, S. McDonald, T. [Pg.217]

Stott. W.T. Kastl, PE. (1986) Inhalation pharmacokinetics of technical grade 1,3-dichloropropene in rats. Toxicol, appl. Pharmacol.. 85, 332-341... [Pg.945]

Woollen. B.H., Marsh, J.R., Mahler, J.D., Auton. T.R., Makepeace, D., Cocker, J. Blain. P.G (1992) Human inhalation pharmacokinetics of chlorodifluoromethane (HCFC22). Int. Arch, occup. environ. Health, 64, 383-387... [Pg.1343]

As discussed above, the main therapeutic value of DNase I is in the treatment of respiratory diseases. As a consequence, most of the pharmacokinetic data available are on the pharmacokinetics of DNase I after inhalation. Pharmacokinetic studies on animals have been reviewed by Green [87]. Inhalation experiments with ihDNase I revealed a low bioavailability of <15% in rats and <2% in monkeys. Studies in rats have indicated that the half-life of rhDNase from the lung is about 11 hours. Based upon the results from a phase I clinical trial, Aitken et al. reported the DNase I concentration in serum only increased slightly after 5 days inhalation of 6-30 mg rhDNase per day [64], The serum DNase levels did not differ significantly from the endogenous serum DNase levels as measured by Sinicropi et al. [88]. This suggested a low systemic exposure of DNase I in... [Pg.297]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...